Dermatrials Research

Recent papers from Dermatrials Research

1. Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsBritish Journal of Dermatology · 2026
2. Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialDermatology and Therapy · 2026
3. Treatment‐associated phenotype switching between psoriasis and atopic dermatitisJournal of the European Academy of Dermatology and Venereology · 2026
4. Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)Dermatology and Therapy · 2026
5. Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN)Rheumatology and Therapy · 2026
6. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque PsoriasisJAMA Dermatology · 2026
7. Understanding Cumulative Life Course Impairment in Canadian Patients With PsoriasisJournal of Cutaneous Medicine and Surgery · 2025
8. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsDermatology and Therapy · 2025
9. Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative ReviewDermatology and Therapy · 2025
10. Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-AnalysisDermatology and Therapy · 2025
11. The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialJournal of Dermatological Treatment · 2025
12. A systematic review of recent randomized controlled trials for palmoplantar pustulosisJournal of Dermatological Treatment · 2024
13. Considerations for defining and diagnosing generalized pustular psoriasisJournal of the European Academy of Dermatology and Venereology · 2024
14. Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective reviewJournal of the American Academy of Dermatology · 2024
15. Predicting psoriasis severity using machine learning: a systematic reviewClinical and Experimental Dermatology · 2024
16. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitisBritish Journal of Dermatology · 2024
17. Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque PsoriasisDermatology and Therapy · 2024
18. Underreporting of sleep variables in psoriasis clinical trialsJEADV Clinical Practice · 2024
19. An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque PsoriasisNew England Journal of Medicine · 2024
20. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline AgentsPharmaceutics · 2024